ASCO: Oncologists better ID long-term effects of chemo

Share this article:
ASCO: Oncologists Better ID Long-Term Effects of Chemo
ASCO: Oncologists Better ID Long-Term Effects of Chemo

(HealthDay News) -- Most oncologists can identify the main late or long-term effects (LEs) of chemotherapy drugs, but primary care physicians (PCPs) are less likely to be able to do so, according to a study released May 16 in advance of presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

Larissa Nekhlyudov, M.D., M.P.H., from Harvard Medical School and Harvard Vanguard Medical Associates in Boston, and colleagues used the Survey of Physician Attitudes Regarding the Care of Cancer Survivors to describe and compare the awareness of 1,072 PCPs and 1,130 oncologists of the LEs of treatment. For each of four standard chemotherapy drugs used to treat breast or colorectal cancer, the respondents (65 percent) were asked to report the five LEs they had observed or seen described in the literature.

The researchers found that the main LEs of all four chemotherapy drugs were identified by 65 percent of oncologists, compared with only 6 percent of PCPs. In adjusted analyses, oncologists who spent 51 to 90 percent or >90 percent of their time on patient care were significantly more likely to identify the main LEs for all chemotherapy drugs (odds ratio [OR], 1.87 and 1.82, respectively). Oncologists who were not board certified and African-American PCPs were less likely to identify the main LEs for all four chemotherapy drugs (adjusted OR, 0.58 and 0.19, respectively).

"While we strongly encourage patients to be aware of the chemotherapy drugs they receive and their side effects, it is vitally important that oncologists relay this information to patients' primary care providers so their risks can be appropriately managed throughout their lives," Nekhlyudov said in a statement. "At the same time, our findings underscore the need for ongoing education among all physicians who care for cancer survivors, including oncologists, about the potential for late effects of treatment."

Abstract
More Information

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Women undergoing morcellation have in 27 in 10k uterine cancer prevalence

Women undergoing morcellation have in 27 in 10k ...

For women undergoing hysterectomy by morcellation, the prevalence of uterine cancers is 27 per 10,000, with increased prevalence with advanced age, according to a research letter published online.

Gene marker may help predict breast cancer response to tamoxifen

Gene marker may help predict breast cancer response ...

Researchers have identified genes that may help predict whether a patient with estrogen receptor (ER)-positive breast cancer is likely to benefit from tamoxifen therapy, according to a study.

Bike riding may up prostate cancer risk

Bike riding may up prostate cancer risk

Researchers found that cyclists who bike more may face a higher risk of prostate cancer, but not a greater chance of infertility or erectile dysfunction.